In vivo analysis of kallikrein-related peptidase 6 (KLK6) function in oligodendrocyte development and the expression of myelin proteins

Neuroscience

Volumn 236, Issue , 2013, Pages 1-11

  Murakami, K ^a   Jiang, Y P ^b,c   Tanaka, T ^a   Bando, Y ^a   Mitrovic, B ^b,d   Yoshida, S ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

^b BAYER AG   (Germany)

^c Cellerant Therapeutics   (United States)

^d VERTEX PHARMACEUTICALS   (United States)

Author keywords

Development; Myelin; Protease; Spinal cord; Spinal cord injury

Indexed keywords

KALLIKREIN 6; MYELIN PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BRAIN SIZE; BRAIN WEIGHT; CELL LINEAGE; CELL MATURATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; GENE FUNCTION; IN VIVO STUDY; KLK6 GENE; MOUSE; NERVE CELL DIFFERENTIATION; NEURAL STEM CELL; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SPINAL CORD; WILD TYPE;

ANIMALS; BLOTTING, WESTERN; CELL DIFFERENTIATION; DISEASE MODELS, ANIMAL; IMMUNOHISTOCHEMISTRY; KALLIKREINS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELIN PROTEINS; OLIGODENDROGLIA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPINAL CORD; SPINAL CORD INJURIES;

EID: 84874344595     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2012.12.073     Document Type: Article

References (47)

1. Anisowicz A., Sotiropoulou G., Stenman G., Mok S.C., Sager R. A novel protease homolog differentially expressed in breast and ovarian cancer. Mol Med 1996, 2:624-636.
2. Bando Y., Ito S., Nagai Y., Terayama R., Kishibe M., Jiang Y.P., Mitrovic B., Takahashi T., Yoshida S. Implications of protease M/neurosin in myelination during experimental demyelination and remyelination. Neurosci Lett 2006, 405:175-180.
3. Basso D.M., Fisher L.C., Anderson A.J., Jakeman L.B., McTigue D.M., Popovich P.G. Basso Mouse Scale for locomotion detects differences in recovery after spinal cord injury in five common mouse strains. J Neurotrauma 2006, 23:635-659.
4. Berger J.R. The basis for modeling progressive multifocal leukoencephalopathy pathogenesis. Curr Opin Neurol 2011, 24:262-267.
5. Bernett M.J., Blaber S.I., Scarisbrick I.A., Dhanarajan P., Thompson S.M., Blaber M. Crystal structure and biochemical characterization of human kallikrein 6 reveals that a trypsin-like kallikrein is expressed in the central nervous system. J Biol Chem 2002, 277:24562-24570.
6. Bhat R.V., Axt K.J., Fosnaugh J.S., Smith K.J., Johnson K.A., Hill D.E., Kinzler K.W., Baraban J.M. Expression of the APC tumor suppressor protein in oligodendroglia. Glia 1996, 17:169-174.
7. Blaber S.I., Scarisbrick I.A., Bernett M.J., Dhanarajan P., Seavy M.A., Jin Y., Schwartz M.A., Rodriguez M., Blaber M. Enzymatic properties of rat myelencephalon-specific protease. Biochemistry 2002, 41:1165-1173.
8. Blaber S.I., Ciric B., Christophi G.P., Bernett M.J., Blaber M., Rodriguez M., Scarisbrick I.A. Targeting kallikrein 6 proteolysis attenuates CNS inflammatory disease. FASEB J 2004, 18:920-922.
9. Borgono C.A., Diamandis E.P. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 2004, 4:876-890.
10. Borgono C.A., Michael I.P., Diamandis E.P. Human tissue kallikreins: physiologic roles and applications in cancer. Mol Cancer Res 2004, 2:257-280.
11. Calver A.R., Hall A.C., Yu W.P., Walsh F.S., Heath J.K., Betsholtz C., Richardson W.D. Oligodendrocyte population dynamics and the role of PDGF in vivo. Neuron 1998, 20:869-882.
12. Chen Z.L., Yoshida S., Kato K., Momota Y., Suzuki J., Tanaka T., Ito J., Nishino H., Aimoto S., Kiyama H., et al. Expression and activity-dependent changes of a novel limbic-serine protease gene in the hippocampus. J Neurosci 1995, 15:5088-5097.
13. Colello R.J., Pott U., Schwab M.E. The role of oligodendrocytes and myelin on axon maturation in the developing rat retinofugal pathway. J Neurosci 1994, 14:2594-2605.
14. Devaux J., Gow A. Tight junctions potentiate the insulative properties of small CNS myelinated axons. J Cell Biol 2008, 183:909-921.
15. Diamandis E.P., Yousef G.M., Clements J., Ashworth L.K., Yoshida S., Egelrud T., Nelson P.S., Shiosaka S., Little S., Lilja H., Stenman U.H., Rittenhouse H.G., Wain H. New nomenclature for the human tissue kallikrein gene family. Clin Chem 2000, 46:1855-1858.
16. Diamandis E.P., Yousef G.M., Petraki C., Soosaipillai A.R. Human kallikrein 6 as a biomarker of Alzheimer's disease. Clin Biochem 2000, 33:663-667.
17. Diamandis E.P., Yousef G.M., Olsson A.Y. An update on human and mouse glandular kallikreins. Clin Biochem 2004, 37:258-260.
18. Du Y., Dreyfus C.F. Oligodendrocytes as providers of growth factors. J Neurosci Res 2002, 68:647-654.
19. Glaser T., Perez-Bouza A., Klein K., Brustle O. Generation of purified oligodendrocyte progenitors from embryonic stem cells. FASEB J 2005, 19:112-114.
20. Gotow T., Leterrier J.F., Ohsawa Y., Watanabe T., Isahara K., Shibata R., Ikenaka K., Uchiyama Y. Abnormal expression of neurofilament proteins in dysmyelinating axons located in the central nervous system of jimpy mutant mice. Eur J Neurosci 1999, 11:3893-3903.
21. Harauz G., Ladizhansky V., Boggs J.M. Structural polymorphism and multifunctionality of myelin basic protein. Biochemistry 2009, 48:8094-8104.
22. Hardy T.A., Blum S., McCombe P.A., Reddel S.W. Guillain-Barre syndrome: modern theories of etiology. Curr Allergy Asthma Rep 2011, 11:197-204.
23. Kucharova K., Stallcup W.B. The NG2 proteoglycan promotes oligodendrocyte progenitor proliferation and developmental myelination. Neuroscience 2010, 166:185-194.
24. Kuhn P.L., Wrathall J.R. A mouse model of graded contusive spinal cord injury. J Neurotrauma 1998, 15:125-140.
25. Lu J., Ashwell K.W., Waite P. Advances in secondary spinal cord injury: role of apoptosis. Spine (Phila Pa 1976) 2000, 25:1859-1866.
26. McKinnon R.D., Matsui T., Dubois-Dalcq M., Aaronson S.A. FGF modulates the PDGF-driven pathway of oligodendrocyte development. Neuron 1990, 5:603-614.
27. McKinnon R.D., Smith C., Behar T., Smith T., Dubois-Dalcq M. Distinct effects of bFGF and PDGF on oligodendrocyte progenitor cells. Glia 1993, 7:245-254.
28. Nishiyama A., Komitova M., Suzuki R., Zhu X. Polydendrocytes (NG2 cells): multifunctional cells with lineage plasticity. Nat Rev Neurosci 2009, 10:9-22.
29. Ontaneda D., Hyland M., Cohen J.A. Multiple sclerosis: new insights in pathogenesis and novel therapeutics. Annu Rev Med 2012, 63:389-404.
30. Padovani-Claudio D.A., Liu L., Ransohoff R.M., Miller R.H. Alterations in the oligodendrocyte lineage, myelin, and white matter in adult mice lacking the chemokine receptor CXCR2. Glia 2006, 54:471-483.
31. Park E., Velumian A.A., Fehlings M.G. The role of excitotoxicity in secondary mechanisms of spinal cord injury: a review with an emphasis on the implications for white matter degeneration. J Neurotrauma 2004, 21:754-774.
32. Redford E.J., Kapoor R., Smith K.J. Nitric oxide donors reversibly block axonal conduction: demyelinated axons are especially susceptible. Brain 1997, 120:2149-2157.
33. Sanchez I., Hassinger L., Paskevich P.A., Shine H.D., Nixon R.A. Oligodendroglia regulate the regional expansion of axon caliber and local accumulation of neurofilaments during development independently of myelin formation. J Neurosci 1996, 16:5095-5105.
34. Schiffmann R., van der Knaap M.S. The latest on leukodystrophies. Curr Opin Neurol 2004, 17:187-192.
35. Shiosaka S., Yoshida S. Synaptic microenvironments-structural plasticity, adhesion molecules, proteases and their inhibitors. Neurosci Res 2000, 37:85-89.
36. Sotiropoulou G., Pampalakis G., Diamandis E.P. Functional roles of human kallikrein-related peptidases. J Biol Chem 2009, 284:32989-32994.
37. Terayama R., Bando Y., Takahashi T., Yoshida S. Differential expression of neuropsin and protease M/neurosin in oligodendrocytes after injury to the spinal cord. Glia 2004, 48:91-101.
38. Terayama R., Bando Y., Jiang Y.P., Mitrovic B., Yoshida S. Differential expression of protease M/neurosin in oligodendrocytes and their progenitors in an animal model of multiple sclerosis. Neurosci Lett 2005, 382:82-87.
39. Terayama R., Bando Y., Yamada M., Yoshida S. Involvement of neuropsin in the pathogenesis of experimental autoimmune encephalomyelitis. Glia 2005, 52:108-118.
40. Terayama R., Bando Y., Murakami K., Kato K., Kishibe M., Yoshida S. Neuropsin promotes oligodendrocyte death, demyelination and axonal degeneration after spinal cord injury. Neuroscience 2007, 148:175-187.
41. Tokumoto Y.M., Durand B., Raff M.C. An analysis of the early events when oligodendrocyte precursor cells are triggered to differentiate by thyroid hormone, retinoic acid, or PDGF withdrawal. Dev Biol 1999, 213:327-339.
42. Totoiu M.O., Keirstead H.S. Spinal cord injury is accompanied by chronic progressive demyelination. J Comp Neurol 2005, 486:373-383.
43. Yamanaka H., He X., Matsumoto K., Shiosaka S., Yoshida S. Protease M/neurosin mRNA is expressed in mature oligodendrocytes. Brain Res Mol Brain Res 1999, 71:217-224.
44. Yamashiro K., Tsuruoka N., Kodama S., Tsujimoto M., Yamamura Y., Tanaka T., Nakazato H., Yamaguchi N. Molecular cloning of a novel trypsin-like serine protease (neurosin) preferentially expressed in brain. Biochim Biophys Acta 1997, 1350:11-14.
45. Yoshida S., Shiosaka S. Plasticity-related serine proteases in the brain (review). Int J Mol Med 1999, 3:405-409.
46. Yousef G.M., Kishi T., Diamandis E.P. Role of kallikrein enzymes in the central nervous system. Clin Chim Acta 2003, 329:1-8.
47. Zeger M., Popken G., Zhang J., Xuan S., Lu Q.R., Schwab M.H., Nave K.A., Rowitch D., D'Ercole A.J., Ye P. Insulin-like growth factor type 1 receptor signaling in the cells of oligodendrocyte lineage is required for normal in vivo oligodendrocyte development and myelination. Glia 2007, 55:400-411.